Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Calldesartan ci1exetil medicine compounds

A technology of candesartan cilexetil and composition, which is applied in the field of candesartan cilexetil composition, can solve the problems of poor stability of candesartan cilexetil, easy hydrolysis, prolonging the validity period of candesartan cilexetil preparations, etc. Effective period, long-term stable effect of inhibition

Active Publication Date: 2008-07-30
QINGDAO HUANGHAI PHARM CO LTD +1
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to overcome the problems of poor stability and easy hydrolysis of candesartan cilexetil in existing candesartan cilexetil preparations, to provide a method that can inhibit the decomposition of candesartan cilexetil and maintain its long-term stability, thereby prolonging candesartan cilexetil. Candesartan cilexetil composition for expiry date of sartan cilexetil formulation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Calldesartan ci1exetil medicine compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] The preparation of embodiment 1 candesartan cilexetil liposome (high pressure emulsifier)

[0018] Candesartan cilexetil 8g, soybean lecithin 20g, dehydrated alcohol 20ml, fully dispersed and emulsified in a high-pressure emulsifier, removed dehydrated alcohol under 50Pa to obtain the candesartan cilexetil liposome composition.

Embodiment 2

[0019] The preparation (ultrasonic wave) of embodiment 2 candesartan cilexetil liposomes

[0020] Candesartan cilexetil 4g, egg yolk lecithin 8g, absolute ethanol 20ml, ultrasonic wave is fully dispersed and emulsified, and dehydrated alcohol is removed under 50Pa to obtain candesartan cilexetil liposome composition.

Embodiment 3

[0021] The preparation of embodiment 3 candesartan cilexetil liposomes (high pressure emulsifier)

[0022] Candesartan cilexetil 8g, soybean lecithin 4g, dehydrated alcohol 20ml, fully dispersed and emulsified in a high-pressure emulsifier, removed dehydrated alcohol under 50Pa to obtain the candesartan cilexetil liposome composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a candesartan ester drug composition which consists of candesartan ester and phospholipids; wherein, the weight of the phospholipid is 0.5 to 10 times that of the candesartan ester; the composition of the invention inserts or wraps the candesartan ester into a central hydrophobic layer of a bimolecular layer of the phospholipid to prepare the candesartan into a candesartan ester liposome composition and the candesartan ester can be prepared into candesartan preparations with suitable pharmaceutical excipient. The composition can prevent the decomposition of the candesartan ester and keep long stability of the candesartan ester so as to prolong the period of validity of the candesartan ester preparations.

Description

technical field [0001] The invention belongs to the field of pharmacy, and in particular relates to an oral candesartan cilexetil composition. Background technique [0002] Candesartan cilexetil is a non-peptide angiotensin II receptor antagonist, because it increases the specificity and selectivity of angiotensin II receptor level blockade in the circulatory system and tissues, it has a higher specificity and selectivity than angiotensin II The more superior characteristics of converting enzyme (ACE) inhibitors do not increase the action of bradykinin caused by ACE enzymes, so they will not cause coughing side effects. [0003] [0004] Candesartan cilexetil structure [0005] In the study of oral preparations of candesartan cilexetil, it was found that its stability was poor, and common preparation technology could not solve the problem of the decomposition of candesartan cilexetil during the preparation process and placement process. Keeping candesartan cilexetil sta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4184A61K47/24A61P43/00A61P9/00
Inventor 高义才孙桂荣吴康苏国强
Owner QINGDAO HUANGHAI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com